Aptevo Therapeutics Inc. reported its financial results for the quarter ended June 30, 2025, and provided a business update. The company highlighted mipletamig's 85% remission rate (11/13 patients) in frontline AML patients across two trials, driving the expansion of its differentiated CD3 portfolio.
The company introduced APVO455, a Nectin-4 x CD3 bispecific for solid tumors, expanding its suite of CRIS-7-derived CD3-engaging molecules. Aptevo's CD3 bispecific portfolio now includes three candidates: mipletamig for AML, APVO442 for prostate cancer, and the newly added APVO455, advancing a targeted, tumor-specific strategy.
Financially, Aptevo completed financings that raised a total of $15.9 million in Q2 2025, extending its cash runway into late Q4 2025. For the six months ended June 30, 2025, the company reported a net loss of $12.612 million and net cash used in operating activities of $13.668 million, contributing to an accumulated deficit of $260.189 million. The company also secured an equity line of credit for up to an additional $25 million in capital.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.